Cloud-Clone Enables mRNA-Engineered EVs to Surmount DMD Therapeutic Barriers: Restoring Full-Length Dystrophin

Cloud-Clone Immunoassay Kit Validates Breakthrough Non-Viral Gene Delivery: Published in Nature Biomedical Engineering

HUSTON, TX, UNITED STATES, September 22, 2026 /EINPresswire.com/ — Wuhan, 2026 — Duchenne muscular dystrophy (DMD) represents a devastating, life-threatening neuromuscular disorder caused by genetic loss-of-function mutations abolishing endogenous dystrophin production. Existing gene-therapy approaches relying on AAV vectors are constrained by packaging limits that only permit delivery of truncated mini-dystrophin constructs. A newly published landmark research work has established skeletal-muscle-targeted engineered extracellular vesicles (t-EVs) capable of efficiently loading full-length DMD mRNA, achieving substantial functional recovery in pre-clinical animal models. Cloud-Clone’s Dystrophin ELISA kit served as a core quantitative analytical tool throughout this study, generating high-precision multi-tissue, cross-species measurements that underpinned key conclusions regarding dose-dependent response, protein persistence and inter-species consistency for this promising therapeutic modality.
Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disease triggered by mutations in the dystrophin (DMD) gene that lead to complete absence of dystrophin protein. Recently, high-impact research has successfully constructed skeletal-muscle-targeted engineered extracellular vesicles (t-EVs) loaded with full-length DMD mRNA. This therapeutic candidate drives fundamental recovery of muscle function in animal models and creates a versatile new non-viral gene-delivery platform for DMD and a broad spectrum of inherited myopathies. The research team adopted Cloud-Clone Mouse Dystrophin ELISA Kit (SEB503Mu) to complete high-precision quantification across multiple tissues in mice and non-human primates. These systematic measurements supported core findings covering dose-dependency, protein durability and cross-species consistency.
This landmark study, titled Skeletal-muscle-targeted non-viral delivery of full-length DMD mRNA for Duchenne muscular dystrophy, has been formally published in the top-tier international journal Nature Biomedical Engineering. This achievement marks a qualitative leap for non-viral full-length gene delivery within DMD therapeutic research. Meanwhile, top-journal-grade experimental data fully validates the outstanding sensitivity, cross-species compatibility and dependable performance of Cloud-Clone immunoassay kits in complex pre-clinical animal studies, demonstrating that Cloud-Clone reagents satisfy stringent quality benchmarks set by world-class scientific research platforms.

Core Research Highlights: Surpassing Large-Gene Delivery Limits to Restore Native Full-Length Protein Instead of Truncated Variants
The research team addressed the critical limitation of AAV systems, which can only package truncated mini-dystrophin transgenes, and implemented a three-pronged innovative technical strategy:
Efficient cargo loading: Using precise Cellular Nanoporation (CNP) technology, the research group efficiently packaged ~12 kb full-length human DMD mRNA into extracellular vesicles. Loading efficiency increased by 800-fold relative to conventional approaches. In primary mdx mouse myoblasts, dystrophin protein expression recovered in a dose-dependent manner toward wild-type levels following treatment. These results confirm that the CNP workflow generates functional EVs carrying full-length DMD mRNA, and myoblasts can effectively internalize these vesicles and translate intact dystrophin protein.

Figure 1. Production and in-vitro functional validation of full-length DMD-mRNA-loaded EVs generated via the CNP platform
Precise tissue targeting: To achieve specific enrichment within skeletal muscle, researchers fused a conserved heptapeptide containing the RGD motif to the N-terminus of CD47, an EV membrane protein engineered to reduce hepatic uptake. The resulting muscle-targeted t-EVs rely on integrin αVβ6-mediated recognition to accumulate preferentially in skeletal muscle, with minimal off-target distribution to heart and liver. These engineered vesicles exhibit superior cellular internalization and lysosomal-escape performance compared with lipid nanoparticles (LNPs), enabling more efficient cytosolic release of delivered mRNA.

Figure 2. t-EV construction and in-vitro / in-vivo targeting validation
Sustained protein expression: mdx mice received intravenous injections of DMD t-EVs combined with the immunosuppressant tacrolimus (FK506), administered twice-weekly for four months. At study endpoint, full-length dystrophin expression in systemic skeletal muscles recovered to nearly 90 % of wild-type levels, with detectable protein persisting for more than 30 days after a single dose. In non-human-primate marmosets, this therapeutic strategy demonstrated robust muscle-targeting behavior and favorable long-term safety profiles, while completely avoiding AAV-associated hepatotoxicity and detrimental immune responses.

Figure 3. t-EV therapy yields superior muscle-functional restoration compared with AAV-mediated mini-dystrophin treatment in mice; safety and targeting profiles of systemic delivery are further validated in marmosets

Core Quantitative Tool: Cloud-Clone Dystrophin ELISA Kit (SEB503Mu)
Within this rigorous pharmacodynamic-evaluation framework, accurate quantification of full-length dystrophin represents the gold-standard readout for judging therapeutic success. The research team leveraged Cloud-Clone SEB503Mu kit to complete a series of critical quantitative assessments:
1.Absolute multi-tissue quantification: Precise measurements across multiple skeletal muscles including tibialis anterior, quadriceps, gastrocnemius and diaphragm in treated mice and marmosets delivered the landmark dataset documenting 89.6 % restoration relative to wild-type dystrophin levels, confirming dose-dependent effects and sustained protein persistence.
2.Long-term kinetic monitoring: Assays spanned a complete time window from 1 day beyond final administration to more than 30 days post-dosing, continuously tracking dynamic dystrophin expression and furnishing solid evidence for durable therapeutic efficacy.
3.Cross-species validation: The identical kit supported quantitative measurements across mouse and non-human-primate specimens, guaranteeing consistency and comparability of datasets ranging from proof-of-concept work through advanced pre-clinical investigations.
Thanks to high sensitivity, strong target specificity and excellent batch-to-batch reproducibility, Cloud-Clone SEB503Mu delivers accurate and trustworthy readouts spanning subcellular protein reconstruction through whole-organ functional assessment, firmly underpinning the core conclusion that non-viral full-length gene delivery can achieve both safety and high therapeutic potency.

Beyond Individual Assay Kits: Cloud-Clone Comprehensive Product Portfolio Empowers the Full Biomedical R&D Value Chain
The outstanding performance of SEB503Mu featured in this high-profile publication exemplifies only one aspect of Cloud-Clone’s research-and-development capabilities. As an innovation-driven life-science enterprise, Cloud-Clone has built an integrated one-stop product-and-service ecosystem:
– Diverse recombinant proteins: Nearly 20 000 independently developed recombinant proteins across multiple species, among which more than 1 000 bioactive proteins are widely deployed for gene-therapy target validation, cellular-function studies and reference-material preparation.
– High-quality antibodies: Affinity-purified monoclonal, polyclonal and recombinant antibodies compatible with Western blot, immunofluorescence, immunohistochemistry and flow cytometry, serving as essential reagents for protein localization and functional characterization.
– Comprehensive immunoassay kits: A complete catalog covering ELISA, CLIA and multiplex assay formats, measuring tens of thousands of analytes such as disease biomarkers, cytokines, myocardial-injury markers and hepatic-renal toxicity markers, delivering standardized solutions for pharmacodynamic testing and pre-clinical safety assessment.
– SPF-grade animal-experiment facilities: Large-scale standardized in-house animal-research center offering thousands of disease models, alongside custom dosing regimens and behavioral analysis services to enable seamless workflows from disease-model establishment to terminal-endpoint measurement.

This study demonstrates that mRNA therapeutics delivered by extracellular vesicles have overcome two major historical hurdles for gene therapy: delivery of oversized genes and the feasibility of repeated non-viral administration. For DMD treatment, this represents a fundamental advancement from partial symptom relief via truncated protein toward full-length dystrophin reconstruction. Cloud-Clone’s in-house-developed assay kit has participated deeply across the full research continuum from basic discovery through translational validation.
Moving forward, guided by the mission “empowering life-science innovation through precise research tools”, Cloud-Clone will keep expanding its product portfolio and support global researchers tackling unmet challenges in genetic disorders and rare-disease research. Insights decoded from biological studies will continue to accelerate the translation of promising discoveries into widely accessible patient therapies.
About Cloud-Clone Corp.
Cloud-Clone Corp. is dedicated to the development and production of high-quality immunoassay reagents and detection solutions. With a focus on antibody engineering, multiplex assay development, and cross-platform compatibility, the company provides research tools designed to support precision medicine and advanced biomedical investigation globally. Our core products and services include the research and development of proteins, antibodies, ELISA kits, primary cells, and multiplex cytokine assay kits, as well as professional CRO services to fully meet the diverse needs of biomedical research and related fields.
For more information about Cloud-Clone Corp, visit www.cloud-clone.com

CLOUD-CLONE CORP.(CCC)
Tel: 001-832-538-0970, 0086-27-8425-9552
Email: mail@cloud-clone.com, sales@cloud-clone.us
Social-media channels:
LinkedIn: https://www.linkedin.com/company/cloud-clone-corp/
Instagram: https://www.instagram.com/cloudclonecorp2023/
TikTok: https://www.tiktok.com/@cloudclonecorp2026

SuKi Duan
CLOUD-CLONE CORP.WUHAN
email us here
Visit us on social media:
LinkedIn
Instagram
TikTok
X

Media gallery